Surface Oncology to Present at Goldman Sachs 39th Annual Global Healthcare Conference

Print
| Source: Surface Oncology, Inc.

CAMBRIDGE, Mass., June 08, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Chief Executive Officer Jeff Goater will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, June 13th at 3:20 p.m. Pacific time.

A live webcast of the discussion will be accessible through Surface Oncology’s Investor Relations website at investors.surfaceoncology.com. A replay of the webcast will be archived on Surface Oncology's website for 30 days following the presentation.

ABOUT SURFACE ONCOLOGY

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies. For more information, please visit www.surfaceoncology.com.

Media Contact:
Paul Goldsmith, Ten Bridge Communications
Paul@Tenbridgecommunications.com
617-697-3479

Investor Contact:
Jessica Fees
JFees@surfaceoncology.com
617-714-4096